Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Apr 9, 2026

Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis
08:00

Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis

Published on: May 26, 2021

14.7K

Cardiovascular Disease Risk in Adults With Hematological Malignancies: A Population-Based Cohort Study Using Linked

Jesse Geels1, Anna van Rhenen2, Clara Gomes3

  • 1Department of Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands; Department of Hematology, Cancer Center, University Medical Center Utrecht, Utrecht, the Netherlands.

Journal of the American College of Cardiology
|April 8, 2026
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial.

The Lancet. Oncology·2026
Same author

αβT/CD19-depleted Allogeneic Stem Cell Transplantation in Adults with Inborn Errors of Immunity.

Journal of clinical immunology·2026
Same author

Posttransplant cells for the win? DLI and adoptive cell therapy to eradicate MRD.

Hematology. American Society of Hematology. Education Program·2025
Same author

Diverging conclusions from risk difference and difference in restricted mean survival time in quantifying absolute treatment effect heterogeneity.

International journal of epidemiology·2025
Same author

Real-world decline in survival with poor guideline adherence in chronic myeloid leukemia care.

Blood cancer journal·2025
Same author

COVID-19 Vaccine Effectiveness in Patients With Hematologic Malignancies: A Nationwide Cohort Study.

The Journal of infectious diseases·2025
Same journal

Aortic Valve Replacement in Women of Reproductive Age.

Journal of the American College of Cardiology·2026
Same journal

Sudden Death in Cardio-Kidney-Metabolic Patients: Insights From FINE-HEART.

Journal of the American College of Cardiology·2026
Same journal

Ultra-Thin Sirolimus-Eluting Versus Everolimus-Eluting Stents in Diabetic Multivessel Coronary Artery Disease Patients: The TUXEDO-2 Trial.

Journal of the American College of Cardiology·2026
Same journal

Reframing Cardiometabolic Risk and Frailty Through Sarcopenic Obesity.

Journal of the American College of Cardiology·2026
Same journal

Imaging-Derived Sarcopenic Obesity and Cardiovascular Outcomes: Insights Into Heart Failure Risk and Muscle Biology.

Journal of the American College of Cardiology·2026
Same journal

The Measure of a Leader: Lessons in Leadership From Eugene Braunwald.

Journal of the American College of Cardiology·2026
See all related articles
This summary is machine-generated.

Patients with hematological malignancies have a significantly higher risk of cardiovascular disease (CVD) compared to the general population. This elevated CVD risk, including heart failure and venous thromboembolism, varies by cancer type and duration.

Area of Science:

  • Hematology
  • Cardiology
  • Oncology

Background:

  • Improved survival in hematological malignancies necessitates focus on long-term complications like cardiovascular disease (CVD).
  • CVD can compromise cancer treatment tolerance and increase patient mortality.

Purpose of the Study:

  • To assess the short- and long-term incidence of cardiovascular disease (CVD) in patients with hematological malignancies.
  • To compare CVD risk between hematological malignancy patients and the general population.

Main Methods:

  • Adult patients diagnosed with common hematological malignancies (1995-2023) were matched with controls.
  • National registries were used to track 11 cardiovascular outcomes.
  • Poisson regression and competing risks models analyzed absolute and relative CVD risk.
Keywords:
cardiovascular diseasesheart failurehematological neoplasmsmyocardial infarctionstrokevenous thromboembolism

More Related Videos

Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models
08:14

Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models

Published on: October 3, 2019

13.2K

Related Experiment Videos

Last Updated: Apr 9, 2026

Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis
08:00

Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis

Published on: May 26, 2021

14.7K
Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models
08:14

Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models

Published on: October 3, 2019

13.2K

Main Results:

  • Heart failure incidence was elevated across all hematological malignancy subtypes, notably in myelodysplastic syndrome and multiple myeloma.
  • Venous thromboembolism risk peaked within the first year post-diagnosis and persisted for up to 5 years.
  • First-year deep venous thrombosis hazard ratios varied significantly by malignancy type, from 3.52 to 34.04.

Conclusions:

  • Hematological malignancy patients and survivors face substantially elevated short- and long-term CVD risks compared to the general population.
  • CVD risk varies significantly by malignancy subtype.
  • Identifying risk drivers is crucial for developing targeted prevention and management strategies.